Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

    Continue investing in technology, people and intellectual property.  We believe that our technological approach to drug discovery, combined with our world class team of scientists spanning various scientific functions, enhances our ability to quickly and effectively discover and develop novel compounds. We have invested significant resources in these areas, including $18.6 million spent on development and enhancement of Contour. We intend to continue to invest in Contour and to recruit the world's leading scientists in order to maintain our leadership in the field. We seek to aggressively protect our assets by broadly filing patent applications that cover the novel discoveries we create.

Product Pipeline

        The following table summarizes key information about our most advanced product candidates:

PRODUCT
CANDIDATE
  INDICATION
(TARGET)
  WORLDWIDE
COMMERCIAL
RIGHTS
  STAGE OF CLINICAL DEVELOPMENT AND
ANTICIPATED MILESTONES
VTP-34072   Type 2 Diabetes and
metabolic syndrome
(11b HSD1)
  BI  

Phase 2 clinical trial initiated in July 2014

Results expected in first half of 2015

             
VTP-37948   Alzheimer's Disease
(BACE)
  BI  

Phase 1 clinical trial initiated in first half of 2014

Phase 1 biomarker trial initiated in first half of 2014

Results for both trials expected in second half of 2014

             
VTP-43742   Psoriasis, Multiple
Sclerosis, other
autoimmune diseases
(RORgt)
  Vitae  

Phase 1 clinical trial expected to begin in first half of 2015

Phase 1 human proof-of-concept results expected by end of 2015

             
VTP-38443   Acute Coronary Syndrome (LXRb)   Vitae  

Phase 1 clinical trial expected to begin in first half of 2016

             
VTP-38543   Atopic Dermatitis (LXRb)   Vitae  

Phase 1 clinical trial expected to begin in second half of 2015

    VTP-34072 Targeting 11b Hydroxysteroid Dehydrogenase Type 1 (11b HSD1) for Type 2 Diabetes and Metabolic Syndrome

    Overview

        VTP-34072, our orally active 11b HSD1 inhibitor, is being developed in collaboration with BI for type 2 diabetes. For FDA regulatory purposes, we expect the indication for VTP-34072 will be for the improvement of glycemic control in type 2 diabetes. However, we believe it will be differentiated from other oral anti-diabetic agents by having a positive impact on multiple cardiovascular and metabolic risk factors associated with metabolic syndrome. Patients with metabolic syndrome, which afflicts approximately 85% of type 2 diabetics, are characterized by being overweight and having elevated glucose, blood pressure, cholesterol and triglycerides, while having decreased levels of HDL-C or "good cholesterol." Individuals with metabolic syndrome have demonstrated abnormalities in cortisol metabolism. Cortisol is synthesized by the adrenal gland and is produced in tissues from the precursor, cortisone, by the enzyme 11b HSD1. This enzyme is present in multiple tissues, especially in liver and adipose tissue. Clinical trials and preclinical studies have shown that 11b HSD1 inhibition can suppress the conversion of inactive cortisone into active cortisol in tissue and thereby reduce cortisol levels in relevant

78